HARROW, INC. (HROWL) - Dilution Analysis

10-Q filing | 37.2M shares outstanding

8-K filing: Harrow, Inc. entered into a Merger Agreement to acquire the remaining equity interests of Melt Pharmaceuticals, Inc., potentially issuing 1,112,000 shares of Harrow's common stock upon receipt of pass-through status awarded and J-Code issuance by the Center for Medicare & Medicaid Services for MELT-300.

10-Q filing | 35.8M shares outstanding

10-K filing | 35.7M shares outstanding

10-Q filing | 35.7M shares outstanding

10-Q filing | 35.6M shares outstanding

10-Q filing | 0.0M shares outstanding

10-K filing | 32.6M shares outstanding

8-K filing: Harrow, Inc. amended its Code of Business Conduct and Ethics, terminated a Loan and Security Agreement with Melt Pharmaceuticals, Inc., and received shares of Melt's Series B-1 and Series B Preferred Stock in settlement of the loan agreement.

10-Q filing | 34.3M shares outstanding

10-Q filing | 35.1M shares outstanding

8-K filing: Harrow Health, Inc. completed a public offering of common stock, selling 3,380,282 firm shares and 507,042 option shares at $17.75 per share, resulting in aggregate gross proceeds of $69.0 million. ($69.0M proceeds)

10-Q filing | 30.3M shares outstanding

8-K filing: Harrow Health, Inc. entered into a Credit and Guaranty Agreement with Oaktree Fund Administration, LLC for a loan of up to $100,000,000, drawing $65,000,000 to repay the B. Riley Loan.

10-K filing | 27.5M shares outstanding

8-K filing: Harrow Health, Inc. completed a registered direct offering of 2,376,426 shares of common stock at $10.52 per share, resulting in gross proceeds of $25,000,002. ($25.0M proceeds)

10-Q filing | 27.3M shares outstanding

10-Q filing | 27.3M shares outstanding

S-3 filing: Harrow Health, Inc. may offer up to $300,000,000 of common stock, preferred stock, depositary shares, warrants, units and debt securities from time to time.

10-Q filing | 27.2M shares outstanding

10-K filing | 27.0M shares outstanding

10-Q filing | 27.1M shares outstanding

S-3 filing: Harrow Health, Inc. may offer up to $125,000,000 of common stock, preferred stock, depositary shares, warrants, units and debt securities in one or more offerings and in any combination.

10-Q filing | 26.9M shares outstanding

8-K filing: Harrow Health, Inc. closed an offering of $17,500,000 aggregate principal amount of 8.625% Senior Notes due 2026 plus an additional $2,500,000 aggregate principal amount of 8.625% Senior Notes due 2026 pursuant to an option to purchase additional Notes, resulting in net proceeds to the Company of approximately $19.6 million and the company used approximately $11.1 million of the net proceeds from the sale of the Notes to redeem all of the outstanding shares of the Company's Series B Cumulative Preferred Stock at $25.00 per share. ($11.1M proceeds)

10-Q filing | 26.0M shares outstanding

8-K filing: Harrow Health, Inc. issued and sold 440,000 shares of Series B Cumulative Preferred Stock to B. Riley Securities, Inc. for a net purchase price of approximately $10.7 million. ($10.7M proceeds)

8-K filing: Harrow Health, Inc. entered into an underwriting agreement with Eton Pharmaceuticals, Inc. and National Securities Corporation for a public offering of 1,320,000 shares of Eton's common stock by Harrow at $7.00 per share, with gross proceeds to Harrow of approximately $9.24 million. The underwriter has an option to purchase an additional 198,000 shares. The offering is expected to close on April 12, 2021. ($9.24M proceeds)

10-K filing | 25.9M shares outstanding

10-Q filing | 25.9M shares outstanding

10-Q filing | 25.9M shares outstanding

S-3 filing: Harrow Health, Inc. may offer from time to time common stock, preferred stock, depositary shares, warrants, units, or debt securities up to an aggregate initial offering price not to exceed $100,000,000.

10-Q filing | 25.9M shares outstanding

10-K filing | 25.3M shares outstanding